Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript

SA Transcripts 161.55K Followers Follow Sarepta Therapeutics, Inc. ( SRPT ) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDT Company Participants Tamara Thornton - Director of Finance, Treasury & Investor Relations Michael Severino - CEO & Director Patrick Moss - Executive VP & Chief Commercial Officer Louise Rodino-Klapac - President of Research & Development and Technical Operations Ryan Wong - Executive VP & CFO James Richardson - Executive VP & Chief Medical Officer Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Brian Abrahams - RBC Capital Markets, Research Division Lin Tsai - Jefferies LLC, Research Division Eliana Merle - Barclays Bank PLC, Research Division Ritu Baral - TD Cowen, Research Division Michael Ulz - Morgan Stanley, Research Division Biren Amin - Piper Sandler & Co., Research Division David Hoang - Deutsche Bank AG, Research Division Andy Chen - Wolfe Research, LLC Luke Lapointe Yanan Zhu - Wells Fargo Securities, LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Yun Zhong - Wedbush Securities Inc., Research Division Presentation Operator Good afternoon and welcome to Sarepta's Second Quarter 2026 Earnings Results Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Sarepta's Senior Director of Investor Relations. Please go ahead. Tamara Thornton Director of Finance, Treasury & Investor Relations Thank you. And thank you all for joining today's call. Earlier this afternoon, we released our financial results for the second quarter of 2026. The press release along with our slides and supplementary information are available on the investor section of our company website. We plan to file a Form 10-Q for the quarter today with the SEC. Joining me on the call are Michael Severino, our CEO, Dr. Louise Rodino-Klapac, President of R&D and Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our Chief Financial Officer. Additionally joining